The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1462
ISSUE 1462
February 16, 2015
Issue 1462
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Diet, Drugs, and Surgery for Weight Loss
February 16, 2015 (Issue: 1462)
Adults with a body mass index (BMI) between
25 and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. Losing even
a small amount of weight and increasing physical
activity can prevent some of the complications
of...more
- CM Apovian et al. Pharmacological management of obesity: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015 January 15 (epub).
- MD Jensen et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2014; 63:2985.
- FM Sacks et al. Comparison of weight-loss diet with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009; 360:859.
- RJ de Souza et al. Effects of 4 weight-loss diets differing in fat, protein, and carbohydrate on fat mass, lean mass, visceral adipose tissue, and hepatic fat: results from the POUNDS LOST trial. Am J Clin Nutr 2012; 95:614.
- BC Johnston et al. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA 2014; 312:923.
- EA Delbridge et al. One-year weight maintenance after significant weight loss in healthy overweight and obese subjects: does diet composition matter? Am J Clin Nutr 2009; 90:1203.
- TM Larsen et al. Diets with high or low protein content and glycemic index for weight-loss maintenance. N Engl J Med 2010; 363:2102.
- MR Lowe et al. Meal replacements, reduced energy density eating, and weight loss maintenance in primary care patients: a randomized controlled trial. Obesity (Silver Spring) 2014; 22:94.
- TA Wadden et al. A two-year randomized trial of obesity treatment in primary care practice. N Engl J Med 2011; 365:1969.
- LJ Appel et al. Comparative effectiveness of weight-loss interventions in clinical practice. N Engl J Med 2011; 365:1959.
- NE Sherwood et al. Enhancing long-term weight loss maintenance: 2 year results from the Keep It Off randomized controlled trial. Prev Med 2013; 56:171.
- SU Dombrowski et al. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ 2014; 348:g2646.
- WC Knowler et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393.
- G Li et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008; 371:1783.
- Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170:1566.
- Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369:145.
- H Jick. Heart valve disorders and appetite-suppressant drugs. JAMA 2000; 283:1738.
- Two drugs for weight loss. Med Lett Drugs Ther 2012; 54:69.
- DB Allison et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity 2012; 20:330.
- KM Gadde et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:1341.
- WT Garvey et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95:297.
- SZ Yanovski and JA Yanovski. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014; 311:74.
- SR Smith et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363:245.
- Contrave – A combination of bupropion and naltrexone for Weight Loss. Med Lett Drugs Ther 2014; 56:112.
- Liraglutide (Victoza) for type 2 diabetes. Med Lett Drugs Ther 2010; 52:25.
- A Astrup et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012; 36:843.
- TA Wadden et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) 2013; 37:1443.
- S Jacob et al. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab. 2009; 11:361.
- WT Garvey et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care 2014; 37:3309.
- PM O’Neil et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012; 20:1426.
- P Hollander et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013; 36:4022.
- Zonisamide (Zonegran) for epilepsy. Med Lett Drugs Ther 2000; 42:94.
- KM Gadde et al. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch Intern Med 2012;172:1557.
- SL McElroy et al. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain. J Clin Psychopharmacol 2012; 32:165.
- Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012; 35:731.
- Drugs for type 2 diabetes. Treat Guidel Med Lett 2014; 12:17.
- J Rosenstock et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010; 33:1173.
- In brief: exenatide (Byetta) for weight loss. Med Lett Drugs Ther 2006; 48:21.
- Pramlintide (Symlin) for diabetes. Med Lett Drugs Ther 2005; 47:43.
- SR Smith et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008; 31:1816.
- Canagliflozin (Invokana) for type 2 diabetes. Med Lett Drugs Ther 2013; 55:37.
- Dapagliflozin (Farxiga) for type 2 diabetes. Med Lett Drugs Ther 2014; 56:13.
- Empagliflozin (Jardiance) for type 2 diabetes. Med Lett Drugs Ther 2014; 56:99.
- PE O’Brien et al. Long-term outcomes after bariatric surgery: fifteen-year follow-up of adjustable gastric banding and a systematic review of the bariatric surgical literature. Ann Surg 2013; 257:87.
- T Diamantis et al. Review of long-term weight loss results after laparoscopic sleeve gastrectomy. Surg Obes Relat Dis 2014; 10:177.
- N Puzziferri et al. Long-term follow-up after bariatric surgery: a systematic review. JAMA 2014; 312:934.
- Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009; 361:445.
- GJ Service et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353:249.
- SH Chang et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003 – 2012. JAMA Surg 2014; 149:275.
- Ottawa (ON): Canadian Agency for Drugs and Technologies in Health 2014 April 24. Bariatric surgical procedures for obese and morbidly obese patients: a review of comparative clinical and cost effectiveness, and guidelines. Available at: www.ncbi. nlm.nih.gov. Accessed February 5, 2015.
- G Mingrone et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012; 366:1577.
- PR Schauer et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366:1567.
- PR Schauer et al. Bariatric surgery versus intensive medical therapy for diabetes – 3 year outcomes. N Engl J Med 2014; 370:2002.
- L Sjöström et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014; 311:2297.
- M Robert et al. Predictive factors of type 2 diabetes remission 1 year after bariatric surgery: impact of surgical techniques. Obes Surg 2013: 23:770.
- L Sjöström et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307:56.
- AE Pontiroli et al. Long-term prevention of mortality in morbid obesity through bariatric surgery. a systematic review and meta-analysis of trials performed with gastric banding and gastric bypass. Ann Surg 2011; 253:484.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1462
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.